Highbridge Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Highbridge Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-10,825	Closed	-$383K	–	1265
2018 Q1	$383K	Hold	10,825	–	–	0.01%	770
2017 Q4	$420K	Buy	+10,825	New	+$412K	0.01%	1024
2017 Q3	–	Sell	-7,500	Closed	-$205K	–	1741
2017 Q2	$205K	Sell	7,500 -6,492	-46%	-$178K	﹤0.01%	1105
2017 Q1	$463K	Sell	13,992 -2,144	-13%	-$54.6K	0.01%	935
2016 Q4	$384K	Sell	16,136 -846	-5%	-$24.2K	0.01%	870
2016 Q3	$623K	Buy	+16,982	New	+$487K	0.01%	706
2015 Q2	–	Sell	-10,196	Closed	-$364K	–	1623
2015 Q1	$364K	Buy	+10,196	New	+$280K	0.01%	1060
2014 Q2	–	Sell	-6,773	Closed	-$263K	–	1256
2014 Q1	$263K	Buy	+6,773	New	+$241K	﹤0.01%	891

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Highbridge Capital Management's RIGL Position: Q2 2018 in Review

Highbridge Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q2 2018, closing a stake of 10,825 shares — an estimated $383K sold.

Highbridge Capital Management first reported a position in RIGL in Q1 2014 and held it in 8 quarters. The position peaked at $623K in Q3 2016. 131 funds tracked by Wall St. Rank hold RIGL as of Q2 2018.

Highbridge Capital Management reported no remaining Rigel Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Highbridge Capital Management sold 10,825 Rigel Pharmaceuticals shares in Q2 2018, an estimated $383K.
Highbridge Capital Management first reported a position in Rigel Pharmaceuticals in Q1 2014 and held it in 8 quarters.
Highbridge Capital Management's Rigel Pharmaceuticals position peaked at $623K in Q3 2016.
131 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.